Compare · DNAY vs HUM
DNAY vs HUM
Side-by-side comparison of Codex DNA Inc. (DNAY) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNAY and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM carries a market cap of $55.40B.
- HUM has hit the wire 14 times in the past 4 weeks while DNAY has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 5 for DNAY).
- Company
- Codex DNA Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- -
- $55.40B
- 1M return
- -
- +11.61%
- 1Y return
- -
- +96.77%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 14
- Recent ratings
- 5
- 25
Codex DNA Inc.
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest DNAY
- SEC Form 4 filed by Kullback William J
- SEC Form 3 filed by new insider Kullback William J
- Codex DNA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Codex DNA Inc.
- Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Codex DNA Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- Herrema Gregory J. was granted 153,191 shares (SEC Form 4)
- SEC Form 3 filed by new insider Herrema Gregory J.
- Codex DNA Inc. filed SEC Form 8-K: Leadership Update
- Codex DNA Inc. filed SEC Form 8-K: Leadership Update
Latest HUM
- Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
- Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
- Humana upgraded by RBC Capital Mkts with a new price target
- Director Frederick Wayne A.I. sold $193,853 worth of Humana Common (440 units at $440.57), closing all direct ownership in the company (SEC Form 4)
- President, Enterprise Growth Dintenfass David gifted 230 units of Humana Common, decreasing direct ownership by 0.91% to 25,177 units (SEC Form 4)
- Chief Legal Officer Ventura Joseph C sold $2,384,013 worth of Humana Common (5,495 units at $433.85) and gifted 437 units of Humana Common, decreasing direct ownership by 22% to 21,473 units (SEC Form 4)
- New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden
- Humana Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities